Edgewise Therapeutics
Drew Scruggs has a diverse range of work experience in the clinical research field. They started their career as an Undergraduate Researcher at St. Jude Children's Research Hospital in 2013, where they focused on abnormal N-linked glycosylation sites and presented their findings. They then joined PRA Health Sciences in 2017 as a Clinical Research Associate, gaining experience in global trials across various therapeutic areas. At PRA, they also took up the role of an In-House Clinical Research Associate, working with pediatrics, rare diseases, and gene therapies. In 2020, Drew transitioned to Imara Inc. as a Sr. Clinical Research Associate and later became a Clinical Project Manager. Currently, they are working at Edgewise Therapeutics as a Manager of Clinical Operations.
Drew Scruggs earned a Bachelor of Science (B.S.) degree in Chemistry from Rhodes College, where they studied from 2012 to 2016.
This person is not in any offices
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.